Table 4.
Edinburgh extended cohort: outcomes for patients with GCA receiving tocilizumab for <12 months, for 12 months and for >12 months
| Parameter | <12 months | 12 months | >12 months |
|---|---|---|---|
| Number of patients receiving tocilizumab | 5 | 9 | 22 |
| Duration of treatment, mean (S.d.), months | 5.5 (1.9) | 12.1 (0.7) | 25.9 (11.9) |
| Achieved CS-free remission, n (%) | 0 (0) | 7 (78) | 9 (41) |
| Number relapsing while receiving tocilizumab | 0 | 0 | 0 |
| Number relapsing after discontinuing tocilizumab | 4 | 1 (4 months after stopping tocilizumab) | 1 (1 month after stopping tocilizumab) |
| Reason for early discontinuation | Hypertension, hypercholesterolaemia, neutropenia, diverticulitis | – | – |